Alterations of Fas (Apo-1/CD95) gene in non-small cell lung cancer

S H Lee1, M S Shin, W S Park

  • 1Department of Pathology, College of Medicine, The Catholic University of Korea, Seoul.

Oncogene
|July 3, 1999
PubMed

Insights

Fas gene mutations, implicated in cell death signaling, were found in 7.7% of non-small cell lung cancers. These alterations may contribute to lung cancer development by disrupting apoptosis.

Area of Science:

  • Molecular Biology
  • Oncology
  • Cell Death Signaling

Background:

  • The Fas receptor (Apo-1/CD95) is crucial for regulating cell death, primarily studied in the immune system.
  • Somatic Fas gene mutations are documented in lymphoid cancers, but non-lymphoid tumors often resist Fas-mediated apoptosis.
  • This resistance suggests potential roles for Fas mutations in non-lymphoid malignancies.

Purpose of the Study:

  • To investigate the presence and nature of Fas gene mutations in non-small cell lung cancer (NSCLC).
  • To determine if Fas gene alterations contribute to the pathogenesis of lung cancer.

Main Methods:

  • Analysis of the entire coding region and splice sites of the Fas gene in 65 human NSCLC samples.
  • Utilized polymerase chain reaction (PCR), single-strand conformation polymorphism (SSCP), and DNA sequencing.
  • Identified missense mutations within the Fas gene.

Main Results:

  • Fas gene mutations were detected in five tumors (7.7%) of the NSCLC cohort.
  • All identified mutations were missense type.
  • Four mutations were in the death domain (cytoplasmic region), and one was in the transmembrane domain.

Conclusions:

  • This is the first report of Fas gene mutations in non-lymphoid malignancies.
  • Fas gene alterations in NSCLC may impair apoptotic function.
  • These findings suggest that Fas gene mutations could play a role in the development of some lung cancers.